Search results for " progress"

showing 10 items of 1287 documents

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis

2022

Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensit…

medicine.medical_specialtyExacerbationbiologicals monoclonal antibodies observational studies precision medicine real-lifeprecision medicineImmunologyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin EAntibodies Monoclonal Humanizedobservational studiechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyCluster AnalysisHumansAnti-Asthmatic Agentsreal-lifeobservational studiesmonoclonal antibodieResponse rate (survey)Bronchiectasisbiologybusiness.industrymedicine.diseaseBenralizumabPhenotypeAsthmaEosinophilsPhenotypechemistrybiologicalsbiology.proteinDisease ProgressionBiomarker (medicine)monoclonal antibodiesbusinessbiological
researchProduct

Cluster headache in relation to different age groups

2019

Cluster headache (CH) has always been considered a type of primary headache affecting predominantly male subjects in early and medium adulthood. However, recent studies carried out in large case series of patients with CH show that not infrequently it may set in also after age 50; by contrast, onset before adolescence is very rare. Additionally, when onset occurs before age 14 or from the sixth decade of life onward, male predominance decreases to the point that in chronic forms CH predominantly affects the female sex. This particular pattern of the gender ratio in relation to onset in different age groups suggests that hormonal factors may actually play a role in the genesis of CH. In part…

medicine.medical_specialtyFuture studiesNeurologyEpidemiologymedicine.drug_classPhysiologyCluster HeadacheDermatology03 medical and health sciences0302 clinical medicinePrimary headacheAge groupsEpidemiologyPrevalencemedicineHumans030212 general & internal medicineAge of Onsetbusiness.industryCluster headacheAge FactorsAge at onsetGeneral Medicinemedicine.diseasePsychiatry and Mental healthEstrogenChronic DiseaseDisease ProgressionNeurology (clinical)businessBiomarkers030217 neurology & neurosurgerySex ratioNeurological Sciences
researchProduct

The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome.

2008

Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in H…

medicine.medical_specialtyHeart diseaseDiseaseBioinformaticsstatin congestive heart failure metabolic sydromeHypolipemiaInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientPharmacologyHeart FailureMetabolic SyndromeClinical Trials as Topicbusiness.industryPublic healthmedicine.diseaseOxidative StressEndocrinologyHeart failureDisease ProgressionMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCurrent pharmaceutical design
researchProduct

Estrogen receptors α (ERα), ERβ and their variants may be responsible for estrogen implication in human liver carcinogenesis and tumor progression

2009

medicine.medical_specialtyHuman liverbusiness.industrymedicine.drug_classEstrogen receptorGeneral MedicineToxicologymedicine.disease_causeEndocrinologyTumor progressionEstrogenInternal medicineMedicinebusinessCarcinogenesisEstrogen receptor alphaEstrogen receptor betaToxicology Letters
researchProduct

Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multice…

2015

Lipoprotein apheresis (LA) can lower LDL-cholesterol and Lp(a) by 60%-70% and is the final escalating option in patients with hyperlipoproteinemias involving LDL or Lp(a) particles. Major therapeutic effect of LA is preventing cardiovascular events. In Germany since 2008 a reimbursement guideline has been implemented accepting to establish the indication for LA not only for familial or severe forms of hypercholesterolemia but also based on Lp(a)-hyperlipoproteinemia associated with a progressive course of cardiovascular disease, that persists despite effective treatment of other concomitant cardiovascular risk factors. The Pro(a)LiFe-study confirmed with a prospective multicenter design tha…

medicine.medical_specialtyHyperlipoproteinemiasTime FactorsDiseaseRisk AssessmentCoronary artery diseasePredictive Value of TestsRisk FactorsInternal medicineMulticenter trialGermanyInternal MedicinemedicineHumansProspective StudiesFamily historyRetrospective Studiesbiologybusiness.industryTherapeutic effectGeneral MedicineGuidelineLipoprotein(a)medicine.diseaseSurgeryTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component RemovalDisease ProgressionCardiology and Cardiovascular MedicineRisk assessmentbusinessBiomarkersLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Calprotectin and spondyloarthritis

2017

medicine.medical_specialtyImmunologyGastroenterologyDisease activity03 medical and health sciences0302 clinical medicineInternal medicineAnimalsHumansImmunology and AllergyMedicineSpondylitis AnkylosingInflammation030203 arthritis & rheumatologyTumor Necrosis Factor-alphabusiness.industryPrognosisInfliximabGene Expression RegulationDisease Progression030211 gastroenterology & hepatologyImmunotherapyCalprotectinbusinessLeukocyte L1 Antigen ComplexBiomarkersExpert Review of Clinical Immunology
researchProduct

Clinical Benefits of Early Triptan Therapy for Migraine

2004

The introduction of the triptans brought advances in achieving complete and sustained pain resolution in migraine patients, compared with non-migraine-specific treatments. However, sustained pain-free rates for triptans recorded in many clinical trials are still relatively low. This may be due to study participants being treated late into the attack, when pain is already moderate or severe. Studies with almotriptan have shown that efficacy is enhanced when treatment is given early in a migraine attack while pain is still mild, compared with later administration when pain intensity is greater. Developments in our understanding of migraine pathophysiology provide a rationale for this phenome…

medicine.medical_specialtyIndolesCentral sensitizationMigraine DisordersTriptans03 medical and health sciences0302 clinical medicinePatient satisfactionIntervention (counseling)AlmotriptanSecondary PreventionmedicineHumans030212 general & internal medicinePractice Patterns Physicians'Intensive care medicineAnalgesicsClinical Trials as TopicEvidence-Based Medicinebusiness.industryDisease progressionGeneral Medicinemedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialTreatment OutcomeMigrainePatient SatisfactionAcute DiseaseDisease ProgressionPhysical therapyNeurology (clinical)businessAttitude to Health030217 neurology & neurosurgerymedicine.drugCephalalgia
researchProduct

OARSI/OMERACT Initiative to Define States of Severity and Indication for Joint Replacement in Hip and Knee Osteoarthritis. An OMERACT 10 Special Inte…

2011

Objective.To define pain and physical function cutpoints that would, coupled with structural severity, define a surrogate measure of “need for joint replacement surgery,” for use as an outcome measure for potential structure-modifying interventions for osteoarthritis (OA).Methods.New scores were developed for pain and physical function in knee and hip OA. A cross-sectional international study in 1909 patients was conducted to define data-driven cutpoints corresponding to the orthopedic surgeons’ indication for joint replacement. A post hoc analysis of 8 randomized clinical trials (1379 patients) evaluated the prevalence and validity of cutpoints, among patients with symptomatic hip/knee OA.…

medicine.medical_specialtyJoint replacementmedicine.medical_treatmentImmunologyPROGRESSIONOsteoarthritisPLACEBO-CONTROLLED TRIAL2-YEARArticlelaw.inventionRADIOGRAPHIC FEATURES03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePhysical medicine and rehabilitationRheumatologyRandomized controlled triallawSeverity of illnessPost-hoc analysismedicinePHYSICAL-FUNCTIONImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyHip surgery3-YEARbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeurosciencePAINASSOCIATIONmedicine.diseaseArthroplasty3. Good healthGLUCOSAMINE SULFATEOSTEOARTHRITIS SEVERITY PAIN FUNCTION STRUCTURE OUTCOME MEASURE placebo-controlled trial double-blind radiographic features glucosamine sulfate physical-function progression pain association 3-year 2-yearOrthopedic surgeryPhysical therapybusiness
researchProduct

Non-alcoholic fatty liver disease pathogenesis: The present and the future

2008

Non-alcoholic fatty liver disease is the clinical hepatic expression of metabolic syndrome. The prevalence of non-alcoholic fatty liver disease is around 20-30%, and with a rapid increase in the metabolic risk factors in the general population, non-alcoholic fatty liver disease has become the most common cause of liver disease worldwide. A fraction (20-30%) of non-alcoholic fatty liver disease patients develop a potentially progressive hepatic disorder, namely non-alcoholic steatohepatitis, leading to end-stage liver disease. The pathogenesis of non-alcoholic fatty liver disease is not entirely understood, and even if insulin resistance is a major pathogenetic key, many other factors are im…

medicine.medical_specialtyLipolysisPopulationPhysiologyApoptosisMitochondria LiverInsulin resistance Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis SteatosisDiseaseFatty Acids NonesterifiedPathogenesisLiver diseaseInsulin resistanceAdipokinesRisk FactorsInternal medicinemedicineAnimalsHumansGenetic Predisposition to Diseaseeducationeducation.field_of_studyHepatologybusiness.industryFatty liverGastroenterologymedicine.diseaseDietFatty LiverOxidative StressEndocrinologyAdipose TissueLiverDisease ProgressionHepatocytesCytokinesInsulin ResistanceSteatohepatitisMetabolic syndromebusinessDigestive and Liver Disease
researchProduct

Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.

2017

The indolent non-Hodgkin lymphomas (i-NHLs) are characterised by ‘indolent’ clinical behaviour with slow growth and prolonged natural history. The watchful waiting (WW) strategy is a frequently employed treatment option in these patients. This implies a strict monitoring by imaging examinations, including 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) and CT. A major concern is radiation exposure due to regularly monitoring by conventional imaging procedures. Several studies have demonstrated the reliability of whole-body magnetic resonance imaging (WB-MRI) for lymphoma staging. WB-MRI could be useful for active surveillance in i-NHLs providing the …

medicine.medical_specialtyLymphomamedicine.medical_treatmentWhole body imaging030218 nuclear medicine & medical imaging03 medical and health sciencesMagnetic resonance imaging0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicinemedia_common.cataloged_instanceHumansRadiology Nuclear Medicine and imagingWhole Body ImagingEuropean unionWatchful WaitingNeuroradiologymedia_commonmedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinReproducibility of ResultsMagnetic resonance imagingInterventional radiologyGeneral Medicinemedicine.diseaseLymphomaRadiation therapyDiffusion Magnetic Resonance Imaging030220 oncology & carcinogenesisDisease ProgressionIonising radiationRadiologybusinessWatchful waitingEuropean radiology
researchProduct